Given that an overactive PI3K pathway is frequently implicated in the development and progression of a variety of malignancies, therapeutic targeting of crucial mediators along the PI3K signaling axis, such as mTOR, is an attractive strategy for cancer therapy. The gene discussed is MTOR; the disease is cancer.